Global Biotechnology Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Global Biotechnology Market Segmentation, By Product Type (Instruments, Reagents, Services, and Software), Technology (Nano Biotechnology, PCR Technology, DNA Sequencing, Chromatography, Tissue Engineering and Regeneration, Cell-Based Assays, Fermentation, and Others), Application (Bio-pharmacy, Bio-industrial, Bio-services, Bioinformatics, and Bio-agriculture), End User (Pharmaceutical and Biotechnology Companies, Contract Research Organizations, Academic and Research Institutes, and Others), Distribution Channel (Direct Tender, Third Party Distributors, and Others) - Industry Trends and Forecast to 2032

Biotechnology Market Size

• The global biotechnology market was valued at USD 1.70 billion in 2024 and is expected to reach USD 13.03 billion by 2032
• During the forecast period of 2025 to 2032 the market is likely to grow at a CAGR of 29.00%, primarily driven by advancements in biotechnological research
• This growth is driven by factors such as AI & machine learning, microbiome research and gene editing & genetic engineering

Biotechnology Market Analysis

• The biotechnology market refers to the industry focused on the application of biological systems, organisms, and cellular processes to develop products and technologies that improve healthcare, agriculture, and industrial manufacturing. This includes genetic engineering, biopharmaceuticals, synthetic biology, and bio-based innovations aimed at enhancing human health, food security, and environmental sustainability
• The industry is expanding due to rising investments in R&D, increasing prevalence of chronic diseases, and growing demand for personalized medicine. As biotechnology continues to drive healthcare and industrial transformations, companies are developing targeted therapies, biosimilars, and bio-manufacturing solutions to meet market needs
• The integration of AI-driven drug discovery, CRISPR gene-editing, and synthetic biology is reshaping the biotechnology landscape by enabling faster drug development, precision medicine, and sustainable alternatives

• For instance, companies such as Moderna and CRISPR Therapeutics are pioneering mRNA-based vaccines and gene-editing therapies, enhancing treatment efficacy and accessibility

• The demand for innovative, eco-friendly, and precision-driven biotechnologies will continue to shape the industry, with companies focusing on cutting-edge research, automation, and personalized solutions to maintain a competitive edge

Report Scope and Biotechnology Market Segmentation        

Biotechnology Market Trends

“Rising Expansion of Synthetic Biology for Sustainable Solutions”

• One prominent trend in the global biotechnology market is the rising expansion of synthetic biology for sustainable solutions
• This trend is driven by the growing need for eco-friendly and bio-based alternatives, pushing biotechnology companies to develop engineered microbes, lab-grown materials, and bio-manufactured chemicals for various industries

• For instance, Ginkgo Bioworks and Zymergen are pioneering synthetic biology applications to create sustainable bio-based chemicals, biodegradable plastics, and alternative proteins for industrial and consumer use

• As industries seek environmentally responsible and resource-efficient solutions, biotech firms are integrating synthetic biology with AI-driven design, automated biofoundries, and precision fermentation to enhance scalability and efficiency
• This shift is expected to accelerate advancements in bio-manufacturing, ensuring long-term market growth as companies focus on sustainability-driven innovations and scalable production technologies to stay competitive in an evolving industry

Biotechnology Market Dynamics

Driver

“Increasing Prevalence of Chronic Diseases”

• The increasing prevalence of chronic diseases, including cancer, diabetes, and autoimmune disorders, is significantly driving the demand for effective therapeutic solutions in the biotechnology market
• As these conditions become more widespread, healthcare providers and patients are seeking innovative treatments that can effectively manage symptoms, enhance quality of life, and improve patient outcomes
• With healthcare systems prioritizing early diagnosis and targeted treatments, biotechnology companies are developing innovative solutions, including monoclonal antibodies, RNA-based therapies, and CRISPR gene-editing techniques, to improve treatment outcomes and patient care
• As chronic disease management evolves, biotechnology firms are leveraging advancements in biomanufacturing, biomarker-driven drug development, and next-generation sequencing to enhance therapeutic precision and treatment efficacy
• Patients and healthcare providers are also emphasizing minimally invasive treatments, biologic drugs, and digital health solutions to ensure better disease monitoring, improved quality of life, and cost-effective healthcare interventions

For instance,

• Moderna and BioNTech have pioneered mRNA-based therapies, revolutionizing vaccine development and expanding the potential for treating infectious and chronic diseases
• Novartis and Bluebird Bio are at the forefront of gene and cell therapies, offering breakthrough treatments for genetic disorders and rare diseases

• With the rising global burden of chronic illnesses and increasing healthcare expenditures, the biotechnology market will continue to experience sustained growth, driving innovation, precision medicine adoption, and the expansion of bio-based therapeutics worldwide

Opportunity

“Technological Advancements in Biotechnology”

• The rising prevalence of chronic diseases is a key driver of growth in the biotechnology market. As the incidence of conditions such as cancer, diabetes, cardiovascular diseases, and genetic disorders continues to increase, the demand for advanced biopharmaceuticals, gene therapies, and precision medicine solutions is accelerating
• With healthcare systems prioritizing early diagnosis and targeted treatments, biotechnology companies are developing innovative solutions, including monoclonal antibodies, RNA-based therapies, and CRISPR gene-editing techniques, to improve treatment outcomes and patient care
• The growing need for personalized and regenerative medicine has led to significant investments in biotechnology R&D, encouraging the development of cell-based therapies, tissue engineering, and AI-driven drug discovery to address the complexities of chronic diseases

For instance,

• Thermo Fisher Scientific is developing advanced sequencing technologies and laboratory automation tools to accelerate genomic research and drug discovery
• Twist Bioscience is leveraging DNA synthesis technology to drive innovations in synthetic biology, supporting applications in drug development, agriculture, and industrial biotechnology

• As biotechnology innovations continue to evolve, companies have the opportunity to develop next-generation therapeutics, eco-friendly bioproducts, and advanced research tools, ensuring continued growth and competitive differentiation in a rapidly advancing market

Restraint/Challenge

“High Research and Development Costs”

• The high costs associated with research and development (R&D) pose a significant challenge for biotechnology companies. Developing biopharmaceuticals, gene therapies, and synthetic biology solutions requires extensive investment in laboratory infrastructure, clinical trials, and regulatory approvals, making it difficult for smaller firms to compete
• Rising expenses related to drug discovery, precision medicine, and biologic manufacturing significantly impact overall development costs, leading to higher treatment prices and extended timelines for bringing new therapies to market. Balancing innovation, affordability, and commercial viability remains a key concern for industry players
• The biotechnology sector also faces financial pressures from regulatory compliance requirements, intellectual property protections, and the cost of obtaining FDA and EMA approvals, which can be lengthy and complex, adding further strain on company budgets

For instance,

• The average cost of developing a new drug, including clinical trials and regulatory approval, is estimated to exceed USD 2 billion, with success rates remaining low due to stringent safety and efficacy standards

• As R&D costs continue to rise, the biotechnology industry will continue to face financial and operational challenges, affecting the pace of innovation and the accessibility of advanced biotechnological solutions

Biotechnology Market Scope

The market is segmented on the basis of product type, technology, application, end user, and distribution channel.

Biotechnology Market Regional Analysis

“North America is the Dominant Region in the Biotechnology Market”

• North America dominates the biotechnology market, driven by the increasing prevalence of chronic diseases, high healthcare expenditure, and strong investments in research and development. The region’s well-established biopharmaceutical industry, advanced healthcare infrastructure, and supportive regulatory framework further solidify its leadership
• The U.S. holds a significant share due to rising cases of cancer, diabetes, and cardiovascular diseases which continue to fuel the demand for innovative biotechnological solutions, including gene therapy, precision medicine, and biopharmaceuticals
• The growing adoption of synthetic biology, AI-driven drug discovery, and CRISPR gene-editing technologies is further shaping the industry in North America, attracting substantial investments from both public and private sectors
• Key biotechnology companies in the region, such as Amgen, Gilead Sciences, and Moderna, continue to drive innovation through extensive R&D initiatives, expanding their portfolios of biologics, cell therapies, and next-generation biopharmaceuticals

“Asia-Pacific is Projected to Register the Highest Growth Rate”

• The Asia-Pacific region is expected to witness the highest growth rate in the biotechnology market, driven by expanding biotech enterprises, increasing government support, and rising healthcare needs
• Countries such as China, India, Japan, and South Korea are emerging as biotechnology hubs, fueled by growing investments in research infrastructure, a rising number of biotech startups, and increased demand for advanced therapeutics
• The rapid adoption of biosimilars, regenerative medicine, and bio-manufacturing technologies is further accelerating market expansion, with governments actively promoting biotech innovation through funding, regulatory support, and industry partnerships
• Leading biotechnology firms in the region, such as WuXi Biologics, Biocon, and Takeda Pharmaceuticals, are expanding their capabilities to meet growing global demand, reinforcing Asia-Pacific’s position as a key player in the biotechnology industry

Biotechnology Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

The Major Market Leaders Operating in the Market Are:

• Abbott (U.S.)
• Agilent Technologies (U.S.)
• Danaher Corporation (U.S.)
• BD (U.S.)
• Bio-Rad Laboratories Inc. (U.S.)
• General Electric Company (U.S.)
• BIOMÉRIEUX (France)
• Lonza (Switzerland)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Hoefer, Inc. (U.S.)
• PerkinElmer Inc. (U.S.)
• Merck KGaA (Germany)
• Promega Corporation (U.S.)
• Quality Biological (U.S.)
• Siemens (Germany)
• Bio-Techne (U.S.)
• TAKARA HOLDINGS INC. (Japan)
• Sysmex Corporation (Japan)
• QuidelOrtho Corporation (U.S.)
• Olympus Corporation (Japan)

Latest Developments in Global Biotechnology Market

• In October 2023, Gilead Sciences, Inc. partnered with Assembly Biosciences to develop innovative therapeutics targeting severe viral diseases. This collaboration aims to leverage both companies' expertise and resources to accelerate the creation of effective treatment options. By combining their strengths, they seek to address critical unmet medical needs in the field of virology and improve patient outcomes
• In September 2023, Merck KGaA formed partnerships with BenevolentAI and Exscientia to utilize artificial intelligence in the drug discovery process. This collaboration focuses on developing new treatments in oncology, neurology, and immunology, aiming to identify innovative candidates for clinical development. By harnessing advanced AI technologies, Merck KGaA hopes to accelerate the discovery of groundbreaking therapeutic options
• In July 2023, Alexion and AstraZeneca Rare Disease entered into an agreement with Pfizer Inc. to acquire preclinical gene therapy programs. This collaboration reinforces their commitment to advancing next-generation genomic medicines by integrating complementary assets and innovative technologies. By pooling resources, the companies aim to accelerate the development of transformative therapies in the field of gene therapy

SKU-66238